Emergent BioSolutions Secures Additional Funding from BARDA to Pursue Post-Exposure Prophylaxis Indication for BioThrax
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has reached an agreement with the Biomedical Advanced Research and Development Authority (BARDA), within the Office of the Assistant...
Emergent BioSolutions to Present at Jefferies 2012 Global Healthcare Conference
May. 22, 2012-- Emergent BioSolutions Inc. (NYSE: EBS) announced today that the company will be webcasting its presentation at the Jefferies 2012 Global Healthcare Conference in New York on Tuesday,...
Emergent BioSolutions Announces Stock Repurchase Program
Emergent BioSolutions Inc. (NYSE: EBS) today announced that its Board of Directors has authorized the repurchase of up to $35 million of the company's common stock from time to time on the open...
Emergent BioSolutions Receives FDA Approval for BioThrax Administered Intramuscularly in a Three-Dose Primary Series Followed by Booster Doses
Emergent BioSolutions Inc. (NYSE: EBS) announced today that the U.S. Food and Drug Administration (FDA) has approved its supplemental Biologics License Application (sBLA) to change the administration...
Emergent BioSolutions to Hold Annual Meeting of Stockholders Thursday, May 17, 2012 at 9:00 AM Eastern; Webcast Will Be Available
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it will hold its Annual Meeting of Stockholders on Thursday, May 17, 2012 beginning at 9:00 AM Eastern at the InterContinental Harbor...
Emergent BioSolutions Reports Financial Results for First Quarter 2012
Total revenues for Q1 2012 were $50.3 million as compared to $18.5 million in 2011. In addition, for Q1 2012 the company recorded a net loss of $6.8 million, or $0.19 per share, as compared to a net...
NATO Emerging Security Challenges Division Partners with Emergent BioSolutions to Host Biopreparedness Workshop at the Counter Terror Expo in London
Emergent BioSolutions Inc. (NYSE:EBS) today announced its support of the North Atlantic Treaty Organization (NATO) Emerging Security Challenges Division (ESCD) in hosting a biopreparedness workshop...
Emergent BioSolutions Executive Chairman Fuad El-Hibri Named Tech Council of Maryland’s Executive of the Year
Emergent BioSolutions Inc. (NYSE: EBS) announced today that Fuad El-Hibri, its executive chairman of the board, has been recognized as Executive of the Year by the Tech Council of Maryland (TCM), the...
Emergent BioSolutions to Release First Quarter 2012 Financial Results and Conduct a Conference Call on May 3, 2012
Company management will host a conference call at 5:00 pm Eastern on May 3, 2012 to discuss the financial results for the first quarter of 2012, recent business developments, revenue guidance for the...
Emergent BioSolutions Receives NIAID Grant to Support Tuberculosis Vaccine Candidate
Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has received a multi-year grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes...
Emergent BioSolutions Reports Financial Results for Fourth Quarter and Full Year 2011
Mar. 8, 2012-- Emergent BioSolutions Inc. (NYSE: EBS) announced today its financial results for the fourth quarter and full year ended December 31, 2011. Total revenues for 2011 were $273.4 million...
Emergent BioSolutions to Present at Cowen and Company Health Care Conference
Emergent BioSolutions Inc. (NYSE: EBS) announced today that the company will be webcasting its corporate overview presentation at the 32nd Annual Cowen and Company Health Care Conference in Boston on...